Cone Rod Dystrophy Market to Register Sustainable Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – MeiraGTx (AAV8-RPGR), Applied Genetic Technologies (AGTC-501)
Key players like MeiraGTx, Applied Genetic Technologies Corp, and others are developing potential therapies for treating Cone Dystrophy. The launch of emerging therapies is expected to significantly impact Cone Rod Dystrophy’s treatment scenario.
DelveInsight’s “Cone Rod Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cone Rod Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Cone Rod Dystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cone Rod Dystrophy: An Overview
Cone rod dystrophies (CRDs) are inherited retinal dystrophies belonging to the pigmentary retinopathies group. CRDs are characterized by retinal pigment deposits visible on fundus examination, predominantly localized to the macular region.
CRD is characterized by primary cone involvement or, sometimes, by concomitant loss of both cones and rods, which explains the predominant symptoms of CRDs. Initial signs and symptoms that usually occur in childhood may include decreased sharpness of vision (visual acuity) and abnormal sensitivity to light (photophobia).
These signs are usually followed by blind spots in the central field of vision (scotomas), loss of color perception, and loss of peripheral vision. Most individuals with this condition are legally blind by mid-adulthood.
There are two main forms of cone dystrophy: stationary cone dystrophy and progressive cone dystrophy. In stationary cone dystrophy, symptoms remain stable and usually present at birth or early childhood. In progressive cone dystrophy, symptoms slowly worsen over time.
Cone Rod Dystrophy Market Key Facts
-
Cone-rod dystrophy (CRD) is a group of related eye disorders that causes vision loss, which becomes more severe over time. According to the National Institutes of Health (n.d.), CRD is estimated to affect 1 in 30,000 to 40,000 individuals.
-
According to the study by Gill et al. (2019), inherited disorders of cone function are classically divided into two subtypes: stationary and progressive. Mutations in 32 genes are reported to cause CRD, among which 6 identified genes predominantly cause CRD and 22 lead to CRD.
-
According to the Orphanet Journal of Rare Diseases, the estimated prevalence of CRDs is 1 in 40,000 in Europe. The four most commonly mutated genes are ABCA4 (1p22.1), responsible for 30 to 60% of autosomal recessive CRDs, CRX (19q13.33), and GUCY2D (17p13.1), responsible for many reported cases of autosomal dominant CRDs, and RPGR (Xp11.4) responsible for X-linked CRDs.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Cone Rod Dystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Cone Rod Dystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cone Rod Dystrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Cone Rod Dystrophy Epidemiology, Segmented as –
-
Total Prevalent Cases of Cone rod dystrophies in the 7MM [2019–2032]
-
Type-specific Cases of Cone rod dystrophies in the 7MM [2019–2032]
-
Diagnosed and treatable cases of Cone rod dystrophies in the 7MM [2019–2032]
-
Inheritance-specific Cases of Cone rod dystrophies in the 7MM [2019–2032]
Cone Rod Dystrophy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Cone Rod Dystrophy market or expected to be launched during the study period. The analysis covers the Cone Rod Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cone Rod Dystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Cone Rod Dystrophy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/cone-rod-dystrophy-market
Leading Companies in the Cone Rod Dystrophy Therapeutics Market Include:
-
AAV8-RPGR: MeiraGTx
-
AGTC-501: Applied Genetic Technologies Corp
And Many Others
Cone Rod Dystrophy Drugs Covered in the Report Include:
-
AAV8-RPGR:
-
AGTC-501
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/cone-rod-dystrophy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cone Rod Dystrophy Competitive Intelligence Analysis
4. Cone Rod Dystrophy Market Overview at a Glance
5. Cone Rod Dystrophy Disease Background and Overview
6. Cone Rod Dystrophy Patient Journey
7. Cone Rod Dystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Cone Rod Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Cone Rod Dystrophy Unmet Needs
10. Key Endpoints of Cone Rod Dystrophy Treatment
11. Cone Rod Dystrophy Marketed Products
12. Cone Rod Dystrophy Emerging Drugs and Latest Therapeutic Advances
13. Cone Rod Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Cone Rod Dystrophy Market Outlook (In US, EU5, and Japan)
16. Cone Rod Dystrophy Access and Reimbursement Overview
17. KOL Views on the Cone Rod Dystrophy Market
18. Cone Rod Dystrophy Market Drivers
19. Cone Rod Dystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/cone-rod-dystrophy-market
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services and Solutions
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
 – DelveInsight | Key Companies – MeiraGTx (AAV8-RPGR), Applied Genetic Technologies (AGTC-501)){kind=link}